Figure 4
From: Hypoxia-mediated impaired erythrocyte Lands’ Cycle is pathogenic for sickle cell disease
Overexpression of LPCAT1 in HSCs of BMT SCD chimeras attenuates sickling, hemolysis, inflammation and tissue damage.
(a–e) LPCAT activity (a), LysoPC content (b), PC content (c), the ratio of LysoPC/PC (d) and the percentage of LysoPC/PL (e) were quantified in the erythrocytes from SCD chimeras with overexpression of LPCAT1 or control vector. Error bars, SEM; n = 6 per group. (f) Overexpression of LPCAT1 in HSCs of BMT SCD chimeras significantly decreased plasma AA levels. (g) Percentages of sickle cells and reticulocytes were significantly reduced in the SCD chimeras overexpressing LPCAT1 in HSCs. (h–k) Overexpression of LPCAT1 in HSCs decreased plasma hemoglobin (h), leukotriene B4 (i), prostaglandin E2 (j) and IL-6 (k) levels in SCD chimeras. Values shown represent the mean ± SEM (n = 6). (l) Hematoxylin and eosin stain shows histological changes in spleen, liver and lung tissues of SCD chimeras 16 weeks after BMT. Scale bar, 10 μm. Values shown represent the mean ± SEM, n = 6 per group. *P < 0.05 versus SCD chimeras with BMCs infected with recombinant lentivirus packaging control vector.
